Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent associated with coronavirus disease, which emerged in late 2019. In response, we developed a diagnostic panel consisting of 3 real-time reverse transcription PCR assays targeting the nucleocapsid gene and evaluated use of these assays for detecting SARS-CoV-2 infection. All assays demonstrated a linear dynamic range of 8 orders of magnitude and an analytical limit of detection of 5 copies/reaction of quantified RNA transcripts and 1 x 10 −1.5 50% tissue culture infectious dose/mL of cell-cultured SARS-CoV-2. All assays performed comparably with nasopharyngeal and oropharyngeal secretions, serum, and fecal specimens spiked with cultured virus. We obtained no false-positive amplifications with other human coronaviruses or common respiratory pathogens. Results from all 3 assays were highly correlated during clinical specimen testing. On February 4, 2020, the Food and Drug Administration issued an Emergency Use Authorization to enable emergency use of this panel.
【저자키워드】 COVID-19, 2019 novel coronavirus disease, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, real-time RT-PCR, Real-time reverse transcription PCR, 【초록키워드】 coronavirus, SARS-COV-2 infection, diagnostic, drug, amplification, serum, Culture, nasopharyngeal, limit of detection, Respiratory pathogens, Oropharyngeal, reverse transcription PCR, False-positive, Emergency use, Nucleocapsid gene, food, Emergency, fecal, acute respiratory syndrome, tissue, specimen, authorization, cultured virus, human coronavirus, Result, performed, evaluated, linear, demonstrated, correlated, magnitude, RNA transcript, quantified, 【제목키워드】 detection, coronavirus 2, PCR, respiratory, US CDC, Panel,